The experimental drug FL118 downregulates MYC and the anti-apoptotic proteins survivin, MCL1 and XIAP [52,53], can modulate immune escape induced by the bone marrow microenvironment [28] and has shown promising pre-clinical activity in MM [27]. This evidence concerns the gene XIAP and Miyoshi myopathy.